Literature DB >> 2950314

Cell cycle control of activated, synchronized murine B lymphocytes--roles of macrophages and complement C3.

F Melchers, A Erdei, C Corbel, M Leptin, T Schulz, M P Dierich.   

Abstract

Three restriction points control the cell cycle of activated murine B lymphocytes in a synergistic way. The first is controlled by the occupancy of surface immunoglobulin either by antigen- or by immunoglobulin-specific antibodies. The second is controlled by the complement C3d receptor CR2 which can be occupied by cross-linked C3b or C3d to stimulate the entry into S phase, or by soluble C3d or a C3 alpha-chain peptide, binding to the CR2 receptor, which inhibit the entry into S phase. Macrophages produce so-called alpha factors which also control the B-cell cycle at the same point. Thus, it is suspected that macrophages produce components of the early pathway of complement activation which finally lead to cross-linking of CR2 receptors on B cells. The third restriction point is controlled by unknown receptors that recognize so-called beta factors produced by helper T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2950314     DOI: 10.1016/0161-5890(86)90148-3

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  4 in total

1.  Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.

Authors:  G Pernegger; T F Schulz; M Hosp; B L Myones; A L Petzer; A Eigentler; G Böck; G Wick; M P Dierich
Journal:  Immunology       Date:  1988-10       Impact factor: 7.397

2.  Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat.

Authors:  J R Pratt; M J Hibbs; A J Laver; R A Smith; S H Sacks
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

3.  Secretion, cleavage and binding of complement component C3 by the human monocytic cell line U937.

Authors:  C M Maison; C L Villiers; M G Colomb
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

4.  A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice.

Authors:  Yong-Gang He; Isabel Y Pappworth; Andreas Rossbach; Joshua Paulin; Tarirai Mavimba; Christine Hayes; Liudmila Kulik; V Michael Holers; Andrew M Knight; Kevin J Marchbank
Journal:  Immunobiology       Date:  2017-10-04       Impact factor: 3.144

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.